By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aquinox Pharmaceuticals 

5600 Parkwood Way
Suite 430
Richmond  British Columbia  V6V 2M2  U.S.A.
Phone: 604-629-9223 Fax: 604-295-4748




Company News
Aquinox Pharmaceuticals (AQXP) Announces Expansion Of Ongoing Phase 2 Trials Of AQX-1125, Including Acceptance Of U.S. IND 6/2/2014 9:22:38 AM
Aquinox Pharmaceuticals (AQXP) To Present At Upcoming Investor Conferences 5/21/2014 9:15:30 AM
Aquinox Pharmaceuticals (AQXP) Announces Closing Of Initial Public Offering 3/12/2014 8:32:46 AM
Vancouver's Aquinox Pharmaceuticals (AQXP) Prices Upsized IPO At $11, Raises $46 Million 3/7/2014 9:32:24 AM
Aquinox Pharmaceuticals Completes $18 Million Series C Financing 4/3/2013 7:33:15 AM
Aquinox Pharmaceuticals Receives Regulatory Clearance to Initiate First Clinical Study of AQX-1125, A Novel Oral Anti-Inflammatory Compound 1/5/2011 9:58:36 AM
Aquinox Pharmaceuticals Appoints Csaba Szabo, M.D., Ph.D., Vice President, Research and Chief Scientific Officer 9/15/2010 12:00:57 PM
Aquinox Pharmaceuticals Completes $25 Million Series B Financing 6/17/2010 7:22:57 AM
Aquinox Pharmaceuticals Completes $14.5 Million Series A Financing 6/12/2007 9:24:26 AM